stoxline Quote Chart Rank Option Currency Glossary
  
HCW Biologics Inc. (HCWB)
1.117  0.017 (1.55%)    06-13 16:00
Open: 1.2158
High: 1.2158
Volume: 11,401
  
Pre. Close: 1.1
Low: 1.0637
Market Cap: 42(M)
Technical analysis
2024-06-13 4:43:50 PM
Short term     
Mid term     
Targets 6-month :  1.37 1-year :  1.5
Resists First :  1.17 Second :  1.28
Pivot price 1.07
Supports First :  1 Second :  0.83
MAs MA(5) :  1.07 MA(20) :  1.08
MA(100) :  1.34 MA(250) :  1.56
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  59.7 D(3) :  42.8
RSI RSI(14): 45.8
52-week High :  2.31 Low :  0.91
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ HCWB ] has closed below upper band by 21.2%. Bollinger Bands are 57.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.22 - 1.22 1.22 - 1.23
Low: 1.05 - 1.06 1.06 - 1.06
Close: 1.11 - 1.12 1.12 - 1.13
Company Description

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Headline News

Tue, 11 Jun 2024
Financial Contrast: Nurix Therapeutics (NASDAQ:NRIX) versus HCW Biologics (NASDAQ:HCWB) - Defense World

Wed, 15 May 2024
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights - Yahoo Finance

Mon, 01 Apr 2024
HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023 - InvestorPlace

Tue, 26 Mar 2024
HCWB Stock Quote Price and Forecast - CNN

Thu, 25 Jan 2024
Several Insiders Invested In HCW Biologics Flagging Positive News - Yahoo Finance

Tue, 14 Nov 2023
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 38 (M)
Held by Insiders 1.785e+007 (%)
Held by Institutions 52.2 (%)
Shares Short 8 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.71e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -665.1 %
Return on Assets (ttm) -47.1 %
Return on Equity (ttm) -132.5 %
Qtrly Rev. Growth 2 %
Gross Profit (p.s.) 627.76
Sales Per Share 4.18085e+006
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -22 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 4.56
Stock Dividends
Dividend 0
Forward Dividend 1310
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android